Format
Sort by
Items per page

Send to

Choose Destination

Best matches for "Fluvoxamine":

The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. Polcwiartek C et al. Psychopharmacology (Berl). (2016)

Quantitative prediction of fetal plasma concentration of fluvoxamine during dosage-tapering to the mother. Matsuoka S et al. Placenta. (2017)

Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders. Altamura AC et al. Expert Opin Drug Metab Toxicol. (2015)

Search results

Items: 1 to 20 of 2858

1.

Pharmacological treatment of attention-deficit hyperactivity disorder comorbid with an anxiety disorder: a systematic review.

Villas-Boas CB, Chierrito D, Fernandez-Llimos F, Tonin FS, Sanches ACC.

Int Clin Psychopharmacol. 2018 Nov 12. doi: 10.1097/YIC.0000000000000243. [Epub ahead of print]

PMID:
30422834
2.

Knowledge of the Pharmacology of Antidepressants and Antipsychotics Yields Results Comparable With Pharmacogenetic Testing.

Macaluso M, Preskorn SH.

J Psychiatr Pract. 2018 Nov;24(6):416-419. doi: 10.1097/PRA.0000000000000345.

PMID:
30395549
3.

[Methods of augmentation of antidepressant therapy (on the model of complex therapy with the inclusion of actovegin) in gerontopsychiatric hospital].

Safarova TP, Yakovleva OB, Sheshenin VS, Gavrilova SI.

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(6. Vyp. 2):55-63. doi: 10.17116/jnevro201811806255. Russian.

PMID:
30346435
4.

Development of a fluvoxamine detection system using a Quenchbody, a novel fluorescent biosensor.

Sasao A, Takaki M, Jeong HJ, Yonemitsu K, Ohtsu Y, Tsutsumi H, Furukawa S, Morioka H, Ueda H, Nishitani Y.

Drug Test Anal. 2018 Oct 17. doi: 10.1002/dta.2520. [Epub ahead of print]

PMID:
30328685
5.

Genetic and pharmacogenetic study of glutamate transporter (SLC1A1) in Iranian patients with obsessive-compulsive disorder.

Abdolhosseinzadeh S, Sina M, Ahmadiani A, Asadi S, Shams J.

J Clin Pharm Ther. 2018 Oct 12. doi: 10.1111/jcpt.12766. [Epub ahead of print]

PMID:
30315580
6.

Navigating the co-prescription of clozapine and fluvoxamine.

Shymko G, Clark V, Shymko L, Waters F.

Schizophr Res. 2018 Sep 28. pii: S0920-9964(18)30299-8. doi: 10.1016/j.schres.2018.05.034. [Epub ahead of print] No abstract available.

PMID:
30269927
7.

A Systematic Review of Evidence-Based Treatments for Prurigo Nodularis.

Qureshi AA, Abate LE, Yosipovitch G, Friedman AJ.

J Am Acad Dermatol. 2018 Sep 24. pii: S0190-9622(18)32628-8. doi: 10.1016/j.jaad.2018.09.020. [Epub ahead of print] Review.

PMID:
30261199
8.

Fourteen-Pound Fluvoxamine-Associated Weight Gain in a Young Woman with Depression and Multiple Anxiety Symptoms.

Jaffe RJ, Juneja NS, Juneja NS, Jaffe RJ, Coffey BJ.

J Child Adolesc Psychopharmacol. 2018 Sep;28(7):488-490. doi: 10.1089/cap.2018.29152.bjc. No abstract available.

PMID:
30226805
9.

Selective serotonin reuptake inhibitors affect structure, function and metabolism of skeletal muscle: A systematic review.

Visco DB, Manhães-de-Castro R, Chaves WF, Lacerda DC, Pereira SDC, Ferraz-Pereira KN, Toscano AE.

Pharmacol Res. 2018 Oct;136:194-204. doi: 10.1016/j.phrs.2018.09.004. Epub 2018 Sep 6. Review.

PMID:
30196103
10.

Real-world effectiveness and safety of aripiprazole augmentation therapy in patients with major depressive disorder.

Kamijima K, Yasuda M, Yamamura K, Fukuta Y.

Curr Med Res Opin. 2018 Dec;34(12):2105-2112. doi: 10.1080/03007995.2018.1519317. Epub 2018 Sep 12.

PMID:
30173568
11.

Interactions of Selective Serotonin Reuptake Inhibitors with β-Amyloid.

Tin G, Mohamed T, Shakeri A, Pham AT, Rao PPN.

ACS Chem Neurosci. 2018 Sep 11. doi: 10.1021/acschemneuro.8b00160. [Epub ahead of print]

PMID:
30157623
12.

Antidepressants in epilepsy.

Górska N, Słupski J, Cubała WJ, Wiglusz MS, Gałuszko-Węgielnik M.

Neurol Neurochir Pol. 2018 Aug 11. pii: S0028-3843(18)30258-5. doi: 10.1016/j.pjnns.2018.07.005. [Epub ahead of print] Review.

PMID:
30131174
13.

Novel ensemble method for the prediction of response to fluvoxamine treatment of obsessive-compulsive disorder.

Hasanpour H, Ghavamizadeh Meibodi R, Navi K, Asadi S.

Neuropsychiatr Dis Treat. 2018 Aug 10;14:2027-2038. doi: 10.2147/NDT.S173388. eCollection 2018.

14.

Cannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders.

Ishiguro H, Horiuchi Y, Tabata K, Liu QR, Arinami T, Onaivi ES.

Molecules. 2018 Jul 24;23(8). pii: E1836. doi: 10.3390/molecules23081836.

15.

Riparin II ameliorates corticosterone-induced depressive-like behavior in mice: Role of antioxidant and neurotrophic mechanisms.

Lopes IS, Oliveira ICM, Capibaribe VCC, Valentim JT, da Silva DMA, de Souza AG, de Araújo MA, Chaves RC, Gutierrez SJC, Barbosa Filho JM, Macêdo DS, de Sousa FCF.

Neurochem Int. 2018 Nov;120:33-42. doi: 10.1016/j.neuint.2018.07.007. Epub 2018 Jul 21.

PMID:
30041016
16.

[Procognitive effects of fluvoxamine: preliminary data].

Bobrov AE, Krasnoslobodtseva LA, Mutnykh EM.

Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(6):43-49. doi: 10.17116/jnevro20181186143. Russian.

PMID:
30040800
17.

Preschool-onset obsessive-compulsive disorder with complete remission.

Miyawaki D, Goto A, Iwakura Y, Hirai K, Miki Y, Asada N, Terakawa H, Inoue K.

Neuropsychiatr Dis Treat. 2018 Jul 3;14:1747-1753. doi: 10.2147/NDT.S169797. eCollection 2018.

18.

Effects of two selected SSRIs on hemorheological parameters in rats.

Arihan O, Yabanoglu SC, Ucar G, Falkmarken ND.

Clin Hemorheol Microcirc. 2018 Jul 11. doi: 10.3233/CH-170353. [Epub ahead of print]

PMID:
30010113
19.

Fluvoxamine.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

20.

Efficacy and tolerability of fluvoxamine in adults with social anxiety disorder: A meta-analysis.

Liu X, Li X, Zhang C, Sun M, Sun Z, Xu Y, Tian X.

Medicine (Baltimore). 2018 Jul;97(28):e11547. doi: 10.1097/MD.0000000000011547. Review.

Supplemental Content

Loading ...
Support Center